DNLI

Denali Therapeutics

Commercial Stage Mixed Mixed
Market Cap
$4.0B
Stage
Commercial Stage
Modality
Mixed
Therapeutic Area
Mixed
Coverage Priority
low
About

Neurodegeneration. Lead: DNL310.

Request Full Coverage

Get detailed pipeline analysis, clinical data breakdowns, competitive landscape, and investment thesis for Denali Therapeutics.

Request Coverage
← Back to All Companies
Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy